Lung cancer drug interaction study aims to uncover safe dosing

NCT ID NCT07685041

Not yet recruiting Knowledge-focused Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This phase 1 trial investigates how HS-10504, an experimental drug for EGFR-mutant non-small cell lung cancer, changes the way the body processes midazolam, a common sedative. About 24 patients with advanced lung cancer who have stopped responding to standard EGFR-targeted therapy will take HS-10504 tablets daily and a single dose of midazolam at two points. By measuring midazolam levels in the blood, researchers hope to understand if HS-10504 affects liver enzymes that break down many drugs, guiding future dosing recommendations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HS-10504
What this could lead to: If successful, this study could help determine safe dosing of HS-10504 with other drugs in lung cancer patients.
What could go wrong: This is a small, early-phase trial focused on drug interactions, not treatment effectiveness. Results may not predict real-world outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC

More trials for these conditions

Other studies related to the condition(s) this trial covers.